Abstracts tagged "cardiovascular disease and tofacitinib"

Abstract Number: 2966 • 2017 ACR/ARHP Annual Meeting
Impact of Tofacitinib Treatment Compared with Placebo or Methotrexate on Cardiovascular Risk Scores in Six Phase 3 Randomized Controlled Trials
Michael Nurmohamed¹, Ernest Choy², Christina Charles-Schoeman³, George Kitas⁴, Paola Accossato⁵, Piotr Szczypa⁶, Konstantina Chouchouli⁷, Tatjana Lukic⁸ and Pinaki Biswas⁸, ¹VU University Medical Centre, Amsterdam, Netherlands, ²CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ³University of California, Los Angeles, Los Angeles, CA, ⁴Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁵Pfizer S.r.l, Rome, Italy, ⁶Pfizer Ltd, Walton Oaks, United Kingdom, ⁷Pfizer Hellas S.A, Neo Psychiko, Greece, ⁸Pfizer Inc, New York, NY
Background/Purpose: Patients (pts) with RA are at increased risk of myocardial infarction and stroke not fully explained by usual cardiovascular (CV) risk factors. Tofacitinib is…